BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio Services, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
JobsRadar was built for real people having a rough time in their job search — not for automated requests. You're clicking way too fast and you're now temporarily blocked.
Come back later. If you're genuinely job hunting, we've got your back — just act like a human.
Cookies & analytics
This site uses cookies from third-party services to deliver its features and to analyze traffic.
Catch your next role the second it’s posted.
Create a free account and we’ll watch the boards for you — the instant a job matches your search, it lands in your inbox or Telegram. No digging, no refreshing.
🔔Instant alerts — by email & Telegram the moment a match goes live
🎯Saved searches — your filters, watched around the clock
🌍Worldwide-remote first — apply from anywhere, before the crowd
